Results 61 to 70 of about 1,016,101 (284)

Advanced Materials for Biologics Delivery to Brain Tumors

open access: yesAdvanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng   +4 more
wiley   +1 more source

Photoacoustic Nanotagging for In Vivo Tracking and Optimization of Macrophage Immunotherapy in Solid Tumors

open access: yesAdvanced Materials, EarlyView.
Macrophage‐based immunotherapy for solid tumors is limited by poor tracking of cell localization and persistence. This study introduces nanotagged macrophages enabling near‐infrared photoacoustic imaging for real‐time monitoring. IFNγ‐conjugated tags enhance antitumor polarization without harming viability.
Seoyoon Song   +8 more
wiley   +1 more source

Modulation of miR‐23b Wnt/β‐catenin Axis Strengthens Endothelial Barrier Properties

open access: yesAdvanced Science, EarlyView.
Early blood‐brain barrier (BBB) disruption contributes to stroke and CNS disease pathology. miR‐23b was identified as a regulator of BBB integrity in brain endothelial cells. Inhibition of miR‐23b enhanced barrier‐associated properties, promoted repair‐related signaling, and reduced BBB leakage in experimental stroke models, supporting further ...
Victor Anthony Martinez   +16 more
wiley   +1 more source

Loss of E3 Ubiquitin Ligase RINES via CpG Methylation Relieves Suppression of STAT3 and MYC, Facilitating Multiple Tumorigeneses

open access: yesAdvanced Science, EarlyView.
Dysregulated protein modifications drive tumorigenesis. RINES, an E3 ubiquitin ligase, represses tumor cell proliferation and metastasis by facilitating RING domain‐dependent, ubiquitin–proteasome‐mediated degradation of STAT3 and MYC, which consequently restrains cancer stemness and oncogenic progression.
Lili Li   +8 more
wiley   +1 more source

Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases

open access: yesJournal of Immunology Research, 2019
Chimeric antigen receptor T (CAR-T) cells are T cells engineered to express specific synthetic antigen receptors that can recognize antigens expressed by tumor cells, which after the binding of these antigens to the receptors are eliminated, and have ...
Yuehong Chen   +4 more
doaj   +1 more source

Artificial Host‐Guest Recognition Directs Glycometabolically Engineered Macrophages to Tumors

open access: yesAdvanced Science, EarlyView.
Glycoengineered supramolecular macrophages (GSAR‐M) are developed using glycometabolic labeling for bioorthogonal host‐guest tumor targeting. This engineering approach unexpectedly enhances macrophage migration, phagocytosis, and pseudopodia formation. Consequently, GSAR‐M demonstrate robust tumor‐targeting specificity, effectively arrest tumor growth,
Zhiqing Yang   +8 more
wiley   +1 more source

Author Correction: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains

open access: yesNature Communications, 2020
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Norris Lam   +5 more
doaj   +1 more source

A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma

open access: yesAdvanced Science, EarlyView.
A double‐layered shell‐core microneedle patch is developed to co‐deliver FOLFIRINOX, surufatinib, and anti‐PD‐1 for localized chemo‐immunotherapy of PDAC. This strategy achieves sustained tumor suppression, reduces metastasis, and reprograms the TME by enhancing CD8+ T‐cell infiltration and inhibiting Tregs and M2 macrophages infiltration, while ...
Tingting Kong   +13 more
wiley   +1 more source

Use of chimeric antigen receptors as a novel cancer immunotherapy approach [PDF]

open access: yes, 2015
Immunotherapy consists of the use of immunologic principles against tumours. Unlike chemotherapy or radiotherapy, immunotherapy has the potential to induce such a dynamic immune response that can kill tumour cells for an extended period of time.
Irazoqui Guimon, Andrea   +1 more
core   +1 more source

Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment

open access: yesAdvanced Science, EarlyView.
This study introduces an innovative strategy for the tumor‐selective catalytic degradation of oncogenic non‐coding RNA by interfacing a ribonuclease‐recruiting small molecule (RIBOTAC) with an EGFR‐targeting nanobody via a CTSB (Cathepsin B)‐responsive linker.
Tianli Luo   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy